{{위키데이터 속성 추적}}
{{Infobox drug|drug_name=|S=3|CAS_number2_Ref={{cascite|correct|CAS}}|CAS_number2=1004316-88-4|PubChem=57327017|DrugBank=|KEGG=D10832|UNII_Ref={{fdacite|correct|FDA}}|UNII=YO603Y8113|UNII2_Ref={{fdacite|correct|FDA}}|UNII2=LW2E03M5PG

<!-- Chemical and physical data -->|C=67|H=90|N=10|O=12|molecular_weight=|CAS_number_Ref={{cascite|correct|CAS}}|SMILES=CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N.CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5|Jmol=|StdInChI=1S/C40H53N7O5S2.C27H37N3O7S/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35;1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49);3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t32-,33-,36+;22-,23-,24+,25-,26+/m10/s1|StdInChI_comment=|StdInChIKey=CXORHDVSJFELCV-HWDLLDTBSA-N|density=|density_notes=|melting_point=|melting_high=|melting_notes=|boiling_point=|boiling_notes=|solubility=|sol_units=|CAS_number=206361-99-1|ATC_suffix=AR14

<!-- Identifiers -->|type=combo

<!-- Combo data -->|pregnancy_category=|component1=다루나비르|class1=[[단백질분해효소 억제제]]|component2=코비시스타트|class2=[[시토크롬 P450]] ([[CYP3A]]) inhibitor

<!-- Clinical data -->|pronounce=|tradename=Rezolsta, Prezcobix|Drugs.com={{drugs.com|ppa|darunavir-and-cobicistat}}|MedlinePlus=|DailyMedID=Prezcobix|pregnancy_AU=B2|pregnancy_AU_comment=<ref name="Drugs.com pregnancy">{{웹 인용| title=Cobicistat / darunavir (Prezcobix) Use During Pregnancy | website=[[Drugs.com]] | date=25 June 2019 | url=https://www.drugs.com/pregnancy/cobicistat-darunavir.html | access-date=19 February 2020}}</ref>|pregnancy_US=N|pregnancy_US_comment=<ref name="Drugs.com pregnancy" />|legal_AU=S4|ATC_prefix=J05|legal_AU_comment=|legal_BR=<!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->|legal_BR_comment=|legal_CA=<!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->|legal_UK=<!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->|legal_US=Rx-only|legal_US_comment=<ref name="Prezcobix FDA label" />|legal_EU=Rx-only|legal_EU_comment=<ref name="Rezolsta EPAR" />|legal_UN=<!-- N I, II, III, IV / P I, II, III, IV-->|legal_NZ=<!--Class A, B, C -->|legal_status=|routes_of_administration=[[구강 투여|월별]]|ATCvet=|specific_rotation=}}

'''다루나비르(Darunavir)/코비시스타트(cobicistat)'''는 미국에서 상품명 '''프레즈코빅스(Prezcobix)''', EU에서 레졸스타'''(Rezolsta)'''로 판매되고 있으며, HIV/AIDS치료와 예방을 위해 고정용량복합제 항레트로 바이러스 약물로 사용되고 있다.<ref name="Prezcobix FDA label">{{웹 인용|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c38fdb6-d0ba-4f16-a0e3-85d9ec334d9f|title=Prezcobix- darunavir ethanolate and cobicistat tablet, film coated|date=6 June 2019|website=DailyMed|access-date=20 February 2020}}</ref>

이 약물은 다루나비르(Darunavir)와 코비시스타트(cobicistat)를 포함한다.<ref name="Prezcobix FDA label" /><ref>{{웹 인용|url=https://aidsinfo.nih.gov/drugs/538/prezcobix/0/patient|title=Darunavir / Cobicistat|work=AIDSinfo|publisher=U.S. Department of Health and Human Services|확인날짜=2021-06-24|archive-date=2020-03-03|archive-url=https://web.archive.org/web/20200303183159/https://aidsinfo.nih.gov/drugs/538/prezcobix/0/patient|url-status=}}</ref><ref name="Drugs.com">{{웹 인용|url=https://www.drugs.com/ppa/darunavir-and-cobicistat.html|title=Darunavir and Cobicistat (Professional Patient Advice)|date=16 September 2019|website=Drugs.com|access-date=19 February 2020}}</ref> 다루나비르(Darunavir)는 HIV 프로테이즈 억제제이고 코비시스타트(cobicistat)는 CYP3A효소에 의해 다루나비르(Darunavir)가 대사되는 것을 차단하는 약물이다.<ref name="Drugs.com" /><ref name="Prezcobix FDA label" />

다루나비르(Darunavir)/코비시스타트(cobicistat)는 2014년 11월에 유럽연합(EU)에서 사용되도록 승인받았으며, 2015년 1월에는 미국에서 사용하도록 승인 받았다.<ref name="Rezolsta EPAR">{{웹 인용|url=https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta|title=Rezolsta EPAR|website=[[European Medicines Agency]] (EMA)|access-date=4 April 2020}}</ref><ref>{{웹 인용|url=http://www.fda.gov/patients/hiv-treatment/antiretroviral-drugs-used-treatment-hiv-infection|title=Antiretroviral drugs used in the treatment of HIV infection|date=12 April 2018|website=U.S. [[미국 식품의약국]] (FDA)|access-date=19 February 2020}}</ref><ref>{{웹 인용|url=https://www.medscape.com/viewarticle/839016|title=Darunavir/Cobicistat (Prezcobix) Combo Pill Clears FDA|date=January 30, 2015|publisher=[[Medscape]]}}</ref><ref name="Prezcobix FDA label" /><ref>{{웹 인용|url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205395Orig1s000TOC.cfm|title=Prezcobix (darunavir and cobicistat) Tablet|date=15 June 2016|website=U.S. [[미국 식품의약국]] (FDA)|access-date=4 April 2020}}</ref>

== 각주 ==
{{각주}}

== 외부 링크 ==

* {{웹 인용|url=https://druginfo.nlm.nih.gov/drugportal/name/cobicistat%20mixture%20with%20darunavir|title=Cobicistat mixture with darunavir|work=Drug Information Portal|publisher=U.S. National Library of Medicine}}
* {{웹 인용|url=https://medlineplus.gov/druginfo/meds/a616029.html|title=Cobicistat|website=MedlinePlus}}
* {{웹 인용|url=https://medlineplus.gov/druginfo/meds/a607042.html|title=Darunavir|website=MedlinePlus}}

{{항레트로바이러스제}}

[[분류:항레트로바이러스 복합제]]